SOLU-CORTEF Sterile Powder is indicated as follows:
*Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate
trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug
hypersensitivity reactions, serum sickness, transfusion reactions.
*Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis
fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
*Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or
cortisone is the drug of choice; synthetic analogs may be used in conjunction with
mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of
particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer,
nonsuppurative thyroiditis.
*Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional
enteritis (systemic therapy) and ulcerative colitis.
*Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid)
hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults
(intravenous administration only; intramuscular administration is contraindicated), pure red cell
aplasia, select cases of secondary thrombocytopenia.
*Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis
with subarachnoid block or impending block when used concurrently with appropriate
antituberculous chemotherapy.
*Neoplastic diseases: For the palliative management of leukemias and lymphomas.
*Nervous System: Cerebral edema associated with primary or metastatic brain tumor, or
craniotomy.
*Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions
unresponsive to topical corticosteroids.
*Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome,
or that due to lupus erythematosus.
*Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when
used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic
pneumonias, symptomatic sarcoidosis.
*Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient
over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis;
ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid
arthritis (selected cases may require low-dose maintenance therapy). For the treatment of
dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
